SPECIAL FEATURES

Highlights of This Issue 3197

CCR Translations

3199 The Dark Side of Innate Immunity Fosters Tumor Growth and Offers New Diagnostic
Ennio Carbone
See related article, p. 3304

3202 One Clever Macrophage Checkpoint
Alberto Mantovani and Raffaella Bonecchi
See related article, p. 3289

CCR Drug Updates

3205 FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Review

3210 Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, Marta Ochoa de Olza, and Elena Garralda

CLINICAL TRIALS: TARGETED THERAPY

3220 Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

CLINICAL TRIALS: IMMUNOTHERAPY

3239 Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréo, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessica J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, and Antoni Ribas

PRECISION MEDICINE AND IMAGING

3247 Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials

3259 Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

3266 Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging
Yixen Xu, Ahmed Hous, Roman Zeleznik, Chintan Parmar, Thibaud Coroller, Idalid Franco, Raymond H. Mak, and Hugo J.W.L. Aerts
3276 Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma

Dipika R. Mohan, Antonio Marcondes Lerario, Tobias Else, Bhramar Mukherjee, Madson Q. Almeida, Michelle Vinco, Juliee Rege, Beatriz M. P. Mariani, Maria Claudia N. Zerbini, Berenice B. Mendonca, Ana Claudia Latronico, Suely K. N. Marie, William E. Rainey, Thomas J. Giordano, Maria Candida B. V. Fragoso, and Gary D. Hammer

3352 Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination

Shelby Lennon, Ayman Oweida, Dallin Milner, Andy V. Phan, Shilpa Bhatia, Benjamin Van Court, Laurel Darragh, Adam C. Mueller, David Raben, Jorge I. Martínez-Torrecuadrada, Todd M. Pitts, Hilary Somerset, Kimberly R. Jordan, Kirk C. Hansen, Jason Williams, Wells A. Messersmith, Richard D. Schulick, Philip Owens, Karyn A. Goodman, and Sana D. Karam

3366 Tissue 2-Hydroxylglutamate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas

Hao-Wen Sim, Romina Nejad, Werjiang Zhang, Farshad Nassiri, Warren Mason, Kenneth D. Aldape, Gelareh Zadeh, and Eric X. Chen

3374 The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases


Table of Contents
Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner

Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck
Jong Woo Lee, Janaki Parameswaran, Teresa Sandoval-Schaefer, Ryung Jin Eoh, Dong-hua Yang, Fang Zhu, Roshan Sharma, Stephen G. Gaffney, Elizabeth B. Perry, Jeffrey P. Townsend, Ilya G. Serebriiskii, Erica A. Golemis, Natalia Issaeva, Wendell G. Yarbrough, Ja Seok Koo, and Barbara Burtness

PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma
Henry G. Smith, David Mansfield, Victoria Roulstone, Joan N. Kyula-Currie, Martin McLaughlin, Radhika R. Patel, Katharina F. Bergerhoff, James T. Paget, Magnus T. Dillon, Aadir Khan, Alan Melcher, Khin Thway, Kevin J. Harrington, and Andrew J. Hayes

B7-H3 Expression in Merkel Cell Carcinoma–Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density

LETTERS TO THE EDITOR

Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Letter
Roberto Ferrara, Sandrine Susini, and Aurelien Marabelle

Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response
Anu Sharma, Sumit K. Subudhi, Jorge Blando, Luis Vence, Jennifer Wargo, James P. Allison, Antoni Ribas, and Padmanee Sharma

ABOUT THE COVER

The cover shows a histological section of a patient-derived xenograft from a pancreatic cancer patient implanted into mice. Stromal fibrosis was assessed by PicroSirius staining and imaging through polarized light. For details, see the article by Lennon and colleagues on page 3352 of this issue.